PCSK-9 inhibitors for hyperlipidemia a review of the comparative clinical effectiveness
Alirocumab and evolocumab are expensive drugs (annual cost per patient > Can
| Main Authors: | , , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2017, June 6, 2017
|
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references